Clinical Trial

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast cancer or subjects who have progressed following treatment free interval of more than 12 months following adjuvant or neoadjuvant treatment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-08-29; most recent amendment 2026-03-09.
Status change: Active, Not Recruiting → Recruiting 2026-03-09
Status change: Recruiting → Active, Not Recruiting 2025-07-30
Status change: Not Yet Recruiting → Recruiting 2022-08-31
Trial Details
NCT Number NCT05524584
Lead Sponsor University of California, Irvine
Conditions Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Enrollment 20 participants
Start Date 2022-08-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-11